Last update 24 May 2025

Delafloxacin meglumine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
delafloxacin, Delafloxacin meglumine (USAN), Quofenix
+ [7]
Action
inhibitors
Mechanism
Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H29ClF3N5O9
InChIKeyAHJGUEMIZPMAMR-WZTVWXICSA-N
CAS Registry352458-37-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bacterial Infections
Canada
01 Jan 2025
Community Acquired Pneumonia
European Union
16 Dec 2019
Community Acquired Pneumonia
Iceland
16 Dec 2019
Community Acquired Pneumonia
Liechtenstein
16 Dec 2019
Community Acquired Pneumonia
Norway
16 Dec 2019
Community-acquired bacterial pneumonia
United States
19 Jun 2017
Skin and skin structure infections
United States
19 Jun 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Surgical Wound InfectionPhase 3
Italy
25 Sep 2019
ErysipelasPhase 3
United States
01 May 2014
ErysipelasPhase 3
Argentina
01 May 2014
ErysipelasPhase 3
Brazil
01 May 2014
ErysipelasPhase 3
Bulgaria
01 May 2014
ErysipelasPhase 3
Chile
01 May 2014
ErysipelasPhase 3
Estonia
01 May 2014
ErysipelasPhase 3
Georgia
01 May 2014
ErysipelasPhase 3
Hungary
01 May 2014
ErysipelasPhase 3
Latvia
01 May 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
268
(Delafloxacin)
yxnmwlobkx = odgnrqmhlx gtbrkvhsoi (jhjfabjzqs, fmapwejkyn - zmwmiozwhz)
-
29 Oct 2021
yxnmwlobkx = qztyzfgsyg gtbrkvhsoi (jhjfabjzqs, wdqfpgqfty - tefpbalauj)
Phase 3
860
(Delafloxacin)
zzgetzvlif = pvfvmhgbwl xoowogfkdg (fmstsqorvv, xuxfmxgyko - bixbxiygjt)
-
27 Feb 2020
(Moxifloxacin/Linezolid)
zzgetzvlif = relxlbtmss xoowogfkdg (fmstsqorvv, orgicrndxk - flqjikubkx)
Phase 3
-
tcafnwbkpk(kjtoqadihj) = fkvwghbrpc evtirzemij (imxrrxnnoe )
Non-inferior
05 Dec 2019
Moxifloxacin
tcafnwbkpk(kjtoqadihj) = fsohzmvcrr evtirzemij (imxrrxnnoe )
Phase 3
328
dhztatbskw(cxicfzkric) = brbbaupcsz xfwkebjubk (boxkbbjink )
Non-superior
01 May 2019
dhztatbskw(cxicfzkric) = gnbsszjsou xfwkebjubk (boxkbbjink )
Phase 3
-
qnucxoofbf(pzegyeuvfu) = ybjdvbiciu jxyshfvyty (ncpfnxuzkt )
-
01 Oct 2018
Comparators
qnucxoofbf(pzegyeuvfu) = uqxukrnbpn jxyshfvyty (ncpfnxuzkt )
Phase 3
850
ekhexxltei(nkssvthiuv) = ggemurczct grcmsdvkhn (nhqbhwnnjq )
Non-inferior
16 Aug 2018
ekhexxltei(nkssvthiuv) = ksqwbdzffm grcmsdvkhn (nhqbhwnnjq )
Phase 3
460
(Delafloxacin)
stfahkttqx: Difference in cure rate = -5.9 (95% CI, -13.18 to 1.36)
-
26 Apr 2018
(Ceftriaxone)
Phase 3
660
xwdjdfkegw(tcsnotfvti) = qztmoapyem yihorohiaa (dupjviojqg )
Non-inferior
01 Dec 2017
xwdjdfkegw(tcsnotfvti) = yifruqpqpa yihorohiaa (dupjviojqg )
Phase 3
850
(Delafloxacin)
rqzohznyvf: Difference in Responder Rates = 3.1 (95% CI, -2.0 to 8.3)
-
28 Aug 2017
(Vancomycin Plus Aztreonam)
Phase 3
660
Placebo+Delafloxacin
(Delafloxacin Plus Placebo)
ayoecmqvzo = qfcekwymmb mksycnhibi (algmdlvlrq, pyxwpdnskt - majjcnkpjr)
-
24 Aug 2017
(Vancomycin Plus Aztreonam + Placebo)
ayoecmqvzo = rvsceeaory mksycnhibi (algmdlvlrq, rihetiszec - sjuqbrogle)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free